IMMP רווח למניה בשנים עשר החודשים האחרונים Immutep Limited ADR

The female cancer treatment sector relies on robust international biomaterial supply chains. Immutep Limited (IMMP) is strengthening its position through physician confidence in its immuno-oncology methods and the recruitment of leading scientists via grant support. The annual net income per share trend visualizes this balance, with the latest value recorded as -7.25, determining the asset's current fundamental value.

The eps_ttm_co metric measures the portion of net income attributable to each share over a trailing twelve-month period, allowing for an assessment of real capital returns while filtering out short-term volatility. By analyzing this chart of net income per share over the last 12 months, an investor can forecast the future margins of Immutep Limited (IMMP), as low protein production costs following FDA approval will create massive operating leverage.